The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: A feasibility trial

Lara‐Corrales, Irene; Parkin, Patricia C.; Stephens, Derek; Hamilton, J. R.; Koren, Gideon; Weinstein, Miriam; Sibbald, R. Gary; Pope, Elena

doi:10.1016/j.jaad.2010.01.047

Cited by 16 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although trimethoprim ultimately failed to achieve statistically significant results against placebo, the authors reported that only 2 of 6 subjects receiving placebo attained "more than 50% reduction in chronic wound area" over the 2-month study period. 11 Compared with these placebo subjects the clinical results achieved in our patient with RDEB whose wound was treated with AFR suggest superiority in both reduction in chronic wound area and time to resolution.…”

Section: Discussionmentioning

confidence: 73%

Case Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing

Krakowski

Ghasri

2015

Pediatrics

View full text Add to dashboard Cite

Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis characterized by generalized skin fragility, severe blistering, and wounding that heals with mutilating scarring. Patients are in constant need of effective wound therapies as they often succumb to aggressive metastatic squamous cell carcinomas or to sepsis that may develop from their chronic wounds. Herein, we demonstrate accelerated wound healing with use of a fractionated CO 2 laser protocol in a 22-year-old man with RDEB. His 9-month-old, non-healing wound decreased from 7 cm in diameter to 2 cm in diameter (a 92% reduction in wound surface area) within 4 weeks of a single laser treatment, and he had near-complete re-epithelialization within 4 weeks of his second laser treatment without blistering or other adverse effects. This novel intervention of using fractionated CO 2 for photo-microdebridement could help revolutionize wound care for patients who have RDEB and whose chronic wounds serve as one of their greatest sources of morbidity and mortality. Dissemination to a pediatric audience is critical so that laser protocols might be more thoroughly investigated and incorporated into wound management strategies for this uniquely vulnerable population.

show abstract

Section: Discussionmentioning

confidence: 73%

Case Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing

Krakowski

Ghasri

2015

Pediatrics

View full text Add to dashboard Cite

show abstract

“…Trimethoprim is an antibiotic that was assessed for its anti-inflammatory effect in a pilot double-blind, randomized, placebo-controlled, crossover trial. Although the study was not adequately powered to achieve statistical significance, the trend showed improved wound healing with trimethoprim compared to placebo, 32 although further work is required to show its clinical benefit to patients in larger trials.…”

Section: Drug Therapymentioning

confidence: 96%

Management of chronic wounds in patients with dystrophic epidermolysis bullosa: challenges and solutions

Rashidghamat¹,

Mellerio²

2017

CWCMR

View full text Add to dashboard Cite

Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of severe inherited blistering diseases that affects 500,000 individuals worldwide. Clinically, individuals with EB have fragile skin and are susceptible to blistering following minimal trauma and show involvement of mucus membrane and other organs in some subtypes. Dystrophic EB (DEB) is divided into 2 major types depending on the inheritance pattern: recessive DEB (RDEB) and dominant DEB (DDEB). RDEB tends to be at the more severe end of the clinical spectrum and has a prevalence of 8 per 1 million of the population, accounting for approximately 5% of all cases of EB. RDEB is caused by loss-of-function mutations in the type VII collagen gene, COL7A1, which leads to reduced or absent type VII collagen (C7) and structurally defective anchoring fibrils at the dermal-epidermal junction. In this review, we will discuss the management of chronic wounds in individuals with DEB, highlighting the changes to practice and the novel therapies that may offer a solution to this debilitating and complex problem which is one of the greatest sources of morbidity in this disease.

show abstract

“…In a proof-of concept double blind randomised cross-over trial comparing trimethoprim to placebo in RDEB, there was a trend towards improved wound healing with trimethoprim compared to placebo (68) although further assessment will be required before trimethoprim might be recommended for routine clinical use. Another preparation that is able to regulate MMP activity in vitro and ex vivo is the green tea extract, epigallocatechin-3-gallate (EGCG) (69).…”

Section: Systemic Treatmentmentioning

confidence: 99%

Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa

Rashidghamat

McGrath

2017

IRDR

View full text Add to dashboard Cite

The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: A feasibility trial

Cited by 16 publications

References 30 publications

Case Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing

Case Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing

Management of chronic wounds in patients with dystrophic epidermolysis bullosa: challenges and solutions

Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa

Contact Info

Product

Resources

About